Genfit S.A. (GNFT): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Genfit S.A. (GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases? This company has revenues of €67.0 million as of December 31, 2024. From its humble beginnings to its current standing in the biotech world, what makes Genfit tick, and how does it generate revenue? Keep reading to uncover the history, ownership structure, mission, operational mechanisms, and revenue streams that define Genfit S.A.

Genfit S.A. (GNFT) History

Genfit S.A. Founding Timeline

Year established

The company was established in 1999.

Original location

The company's original location was in Lille, France.

Founding team members

The founding team members included:

• Jean-François Mouney, who served as Chairman and CEO.
• Bart Staels, a Professor at the University of Lille.

Initial capital/funding

Details regarding the initial capital and funding are not readily available in the provided context. Further research would be needed to accurately state the initial financial backing of the company.

Genfit S.A. Evolution Milestones

Genfit S.A. Transformative Moments

• Strategic Shift to NASH: A pivotal moment was the strategic focus on developing treatments for NASH, a significant unmet medical need.
• Elafibranor Development: The development and clinical trials of elafibranor marked crucial phases, especially the positive Phase 3 results that underscored its potential.
• Acquisition by Ipsen: The acquisition by Ipsen in 2024 was a transformative moment, providing financial backing and resources to further develop and commercialize its pipeline.
• FDA Submission for Elafibranor: The submission of the NDA to the FDA for elafibranor in PBC represents a critical step towards potential market approval and commercialization.

To gain more insights into the investors and the reasons behind their investment decisions, check out this resource: Exploring Genfit S.A. (GNFT) Investor Profile: Who’s Buying and Why?

Genfit S.A. (GNFT) Ownership Structure

Understanding the ownership structure of Genfit S.A. provides key insights into the company's control and strategic direction. The company's shares are held by a mix of institutional and individual investors.

Genfit S.A.'s Current Status

Genfit S.A. is a public company, trading on the Nasdaq Global Select Market under the ticker symbol GNFT. This allows the public to invest in the company, and its financial performance is subject to public reporting requirements.

Genfit S.A.'s Ownership Breakdown

As a publicly traded company, the ownership of Genfit S.A. is distributed among various shareholders. The following table summarizes the estimated ownership breakdown based on the latest available data:

Genfit S.A.'s Leadership

The leadership team at Genfit S.A. is responsible for guiding the company's strategy and operations. Key members of the leadership team include:

• Pascal Prigent: Chief Executive Officer
• Sébastien Bardot: Chief Financial Officer

These individuals, along with other members of the executive team, play a crucial role in the company's decision-making process and overall performance. For additional insights into Genfit S.A.'s financial standing, consider exploring: Breaking Down Genfit S.A. (GNFT) Financial Health: Key Insights for Investors

Genfit S.A. (GNFT) Mission and Values

Genfit S.A. focuses on discovering and developing therapeutic solutions in areas of high unmet medical needs, particularly in metabolic and liver diseases. The company is dedicated to improving patients' lives through innovative science and personalized medicine.

Genfit S.A.'s Core Purpose

Official mission statement

While a direct, concise mission statement for Genfit S.A. isn't explicitly available, their activities and focus suggest a mission centered around:

• Developing innovative therapies for metabolic and liver diseases.
• Advancing scientific understanding of these complex conditions.
• Improving patient outcomes through personalized medicine approaches.

Vision statement

Similarly, a specific vision statement isn't formally published, but inferred from their strategic goals, the vision can be described as:

• Becoming a leader in the treatment of liver and metabolic diseases.
• Pioneering innovative diagnostic and therapeutic solutions.
• Transforming patient care through precision medicine.

Company slogan/tagline

There is no widely recognized official slogan or tagline for Genfit S.A. However, considering their focus, a potential informal tagline could be:

• 'Innovating for Liver and Metabolic Health.'
• 'Advancing Science, Improving Lives.'

To gain more insights into the company's financial standing, explore: Breaking Down Genfit S.A. (GNFT) Financial Health: Key Insights for Investors

Genfit S.A. (GNFT) How It Works

Genfit S.A. is a biopharmaceutical company focused on discovering and developing therapeutic solutions for metabolic and liver diseases, primarily targeting conditions with significant unmet medical needs. The company operates through research and development, clinical trials, and strategic partnerships to bring innovative treatments to market.

Genfit's Product/Service Portfolio

Genfit's Operational Framework

Genfit's operational framework is built around several core activities:

• Research and Development: Investing heavily in identifying and developing novel therapeutic targets and drug candidates. This includes preclinical studies and early-stage clinical trials.
• Clinical Trials: Conducting rigorous Phase 1, 2, and 3 clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are crucial for obtaining regulatory approvals.
• Regulatory Affairs: Navigating the complex regulatory landscape to secure approvals from agencies like the FDA in the United States and the EMA in Europe.
• Partnerships and Licensing: Collaborating with other pharmaceutical companies and research institutions to expand its pipeline, share risks, and access new markets.
• Manufacturing and Supply Chain: Establishing manufacturing processes and supply chains to ensure the availability of its products upon regulatory approval.

Genfit's operational processes drive value creation by:

• Advancing drug candidates through the clinical development pipeline.
• Generating data to support regulatory submissions.
• Building strategic partnerships to expand its reach and capabilities.
• Protecting its intellectual property through patents and other forms of protection.

Genfit's Strategic Advantages

Genfit's strategic advantages include:

• Proprietary Technology: The NIS4 technology platform provides a competitive edge in identifying and validating drug targets and biomarkers.
• Focus on NASH: A strategic focus on NASH, a disease with a high unmet medical need and a growing patient population.
• Experienced Management Team: A leadership team with extensive experience in drug development, regulatory affairs, and commercialization.
• Strategic Partnerships: Collaborations with leading pharmaceutical companies and research institutions enhance its capabilities and expand its market reach.
• Versatility™ Platform: Advanced clinical trial platform optimizing patient selection and treatment monitoring.

For more in-depth insights, check out: Exploring Genfit S.A. (GNFT) Investor Profile: Who’s Buying and Why?

Genfit S.A. (GNFT) How It Makes Money

Genfit S.A. primarily generates revenue through the development and commercialization of therapeutic solutions, particularly in the areas of liver diseases.

Genfit S.A.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, revenue streams for Genfit can vary significantly year to year, especially as they approach commercializing new therapies. Revenue recognition typically occurs through collaboration agreements, licensing deals, and milestone payments. Keep in mind that the information below reflects the most recent data available up to April 2025.

Genfit S.A.'s Business Economics

Genfit operates within the competitive biopharmaceutical industry, where success hinges on:

• Intellectual Property: Protecting proprietary drug candidates is crucial.
• Clinical Trial Outcomes: Positive results drive valuation and partnership opportunities.
• Regulatory Approvals: Securing approvals from agencies like the FDA and EMA is essential for commercialization.
• Partnerships: Collaborations with larger pharmaceutical companies can provide funding and market access.

Genfit S.A.'s Financial Performance

Evaluating Genfit’s financial health involves assessing several key factors:

• Cash Runway: The amount of cash available to fund operations until profitability or further financing.
• R&D Expenses: Significant investment in research and development is typical for biopharmaceutical companies.
• Net Losses: As a development-stage company, Genfit may experience net losses until products are commercialized.
• Financing Activities: Monitoring how the company raises capital (e.g., equity offerings, debt financing) is important.

For further insights into Genfit's financial standing, you can explore this analysis: Breaking Down Genfit S.A. (GNFT) Financial Health: Key Insights for Investors

Genfit S.A. (GNFT) Market Position & Future Outlook

Genfit S.A. is navigating a complex landscape in the biopharmaceutical industry, with a focus on liver diseases. The company's future hinges on successful clinical trials, regulatory approvals, and strategic partnerships.

Competitive Landscape

Opportunities & Challenges

Industry Position

Genfit S.A. holds a position as a specialized player within the biopharmaceutical sector, specifically targeting liver diseases. The company's standing is characterized by:

• NASH Focus: A strong emphasis on developing treatments for Non-Alcoholic Steatohepatitis (NASH).
• Elafibranor: Potential blockbuster drug, currently under regulatory review for Primary Biliary Cholangitis (PBC).
• Research Pipeline: Ongoing research and development efforts to expand its portfolio of liver disease treatments.

To gain more insights into the investors behind the company, consider reading: Exploring Genfit S.A. (GNFT) Investor Profile: Who’s Buying and Why?